Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events-Reference-Cited by-同舟云学术

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events

Published:2019-02 Issue:4 Volume:73 Page:387-396
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Szarek Michael,White Harvey D.,Schwartz Gregory G.,Alings Marco,Bhatt Deepak L.,Bittner Vera A.,Chiang Chern-En,Diaz Rafael,Edelberg Jay M.,Goodman Shaun G.,Hanotin Corinne,Harrington Robert A.,Jukema J. Wouter,Kimura Takeshi,Kiss Robert Gabor,Lecorps Guillaume,Mahaffey Kenneth W.,Moryusef Angèle,Pordy Robert,Roe Matthew T.,Tricoci Pierluigi,Xavier Denis,Zeiher Andreas M.,Steg Ph. Gabriel

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference11 articles.

1. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial;Tikkanen;J Am Coll Cardiol,2009

2. Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes

3. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial);LaRosa;Am J Cardiol,2010

4. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial;Murphy;J Am Coll Cardiol,2016

5. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome;Schwartz;Eur J Prev Cardiol,2017

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction;Journal of the American College of Cardiology;2024-09

2. Deciphering PCSK9 and LDLR Gene Expression in Coronary Artery Disease Patients: Implications for Blood Lipid Regulation;2024-08-09

3. In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme;European Journal of Preventive Cardiology;2024-08-05

4. The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development;JACC: Basic to Translational Science;2024-08

5. Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review;Cardiovascular Drugs and Therapy;2024-06-29